U.S. markets closed

Harpoon Therapeutics, Inc. (HARP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.02-0.36 (-2.34%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close15.38
Open15.37
Bid14.97 x 1300
Ask15.01 x 1100
Day's Range14.54 - 15.60
52 Week Range10.55 - 25.24
Volume1,848,809
Avg. Volume305,473
Market Cap488.507M
Beta (5Y Monthly)0.83
PE Ratio (TTM)N/A
EPS (TTM)-3.71
Earnings DateAug 03, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.30
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Harpoon Therapeutics'(NASDAQ:HARP) Share Price Is Down 13% Over The Past Year.
    Simply Wall St.

    Harpoon Therapeutics'(NASDAQ:HARP) Share Price Is Down 13% Over The Past Year.

    It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...

  • Harpoon's TriTAC Programs Show Reduction in Tumor Size, Stable Disease Across Solid Tumors
    Benzinga

    Harpoon's TriTAC Programs Show Reduction in Tumor Size, Stable Disease Across Solid Tumors

    Harpoon Therapeutics Inc (NASDAQ: HARP) provides updated interim data from the ongoing dose-escalation portion of the Phase 1/2a trial for HPN424 in patients with metastatic castration-resistant prostate cancer (mCRPC). Data were presented at the American Society of Clinical Oncology Virtual Annual Meeting. 15/74 (20%) patients had a prostate-specific antigen (PSA) decreases from baseline ranging from -2% to -76%, including four patients with PSA50 response and two patients with PSA30 response T

  • Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTAC™ Platform
    GlobeNewswire

    Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTAC™ Platform

    Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment durationAll four clinical programs demonstrate half-life extension, target engagement and T cell activationCytokine release syndrome observed and manageable, with low incidence of severe CRSManagement to host webcast and conference call to review the interim data presented at ASCO and provide a pipeline update today at 4 p.m. ET /1 p.m. PT SOUTH SAN FRANCISCO, C